Studying Gene Expression in Samples From Patients With Rhabdoid Tumors

Determination of the Frequency of BRG1 and BRM Loss in Rhabdoid Tumors

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01553175

Enrollment

Registered

2012-03-14

Start date

2012-03-31

Completion date

Unknown

Last updated

2016-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain and Central Nervous System Tumors, Kidney Cancer

Keywords

childhood atypical teratoid/rhabdoid tumor, rhabdoid tumor of the kidney

Brief summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and find biomarkers related to cancer. It may also help doctors find better ways to treat cancer. PURPOSE: This research trial studies gene expression in samples from patients with rhabdoid tumors.

Detailed description

OBJECTIVES: * To determine if BRM is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors. * To determine if BRG1 is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors. * To determine if GATA1 and/or HDAC2 is overexpressed in the same tumors that lack BRM expression. * To determine if BRM promoter polymorphisms correlate with loss of BRM expression in primary rhabdoid tumors. * To determine how BRG1 is silenced in primary rhabdoid tumors by sequencing BRG1 exons in genomic DNA derived from frozen samples. OUTLINE: Archived tumor tissue samples are analyzed for BRM, BRG1, GATA1, and/or HDAC2 expression by immunohistochemistry. BRM- and BRG1-negative samples are also analyzed.

Interventions

GENETICDNA analysis

GENETICgene expression analysis

GENETICmutation analysis

GENETICprotein expression analysis

OTHERimmunohistochemistry staining method

OTHERlaboratory biomarker analysis

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 120 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Tumor samples from patients diagnosed with rhabdoid tumors * Matched frozen tumor tissue from BRG1-negative tumors (preferred) or matched genomic DNA from tumors, 100 ng per tumor from BRG1-negative tumors * Any source of DNA from BRG1-negative tumors (tumors, blood, etc.) * Matched frozen tumor tissue from BRM-negative tumors to confirm that BRM is not mutated or altered but rather epigenetically suppressed when lost in rhabdoid tumors PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

Measure	Time frame
Absence or presence BRG1 and BRM expression in rhabdoid tumors	—
Mechanism of suppression of BRG1 and BRM genes	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026